Preview

Медицинский Совет

Расширенный поиск

Самоконтроль при сахарном диабете - основа успешного управления заболеванием

https://doi.org/10.21518/2079-701X-2014-2-62-67

Полный текст:

Аннотация

В 2011 г. распространенность сахарного диабета достигла 366 млн человек и при сохранении современных темпов роста вырастет до 552 млн в 2030-м [1]. Сахарный диабет и его осложнения -одна из главных причин смертности в большинстве развитых стран, и есть существенные доказательства, что увеличение распространенности диабета и его осложнений может принять эпидемический характер в развивающихся государствах. Неконтролируемый сахарный диабет связан с развитием макрососудистых осложнений, потерей зрения, развитием хронической почечной недостаточности, нейропатии и ростом числа ампутаций нижних конечностей [2-6]. Именно макрососудистые осложнения - основная причина смерти у людей с диабетом [7].

Об авторе

И. А. Барсуков
МБУЗ «Химкинская центральная клиническая больница», Московская обл
Россия


Список литературы

1. Whiting D, Guariguata L, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 2011, 93:December (in press).

2. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med, 1993, 329: 977-986.

3. Ohkubo Y, Kishikawa H, Araki E, Miyata T,Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin- dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract, 1995, 28: 103-117.

4. UK Prospective Diabetes Study (UKPDS) Group. In-tensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UK-PDS 33). Lancet, 1998, 352: 837-853.

5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352: 854-865.

6. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective co-hort studies. BMJ, 2006, 332: 73-78.

7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339: 229-234.

8. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353: 2643-2653.

9. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke, 2004; 35: 1073-1078.

10. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J, 2006, 152: 27-38.

11. Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of longterm complications: the perspective of the Diabetes Control and Complications Trial. Diabetes, 1996, 45: 1289-1298.

12. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321: 405-412.

13. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european pro-spective investigation of cancer and nutrition (EPIC-Norfolk). BMJ, 2001, 322: 15-18.

14. Gerstein HC. Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evid Based Cardiovasc Med, 1997, 1: 87-88.

15. Punthakee Z, Werstuck GH, Gerstein HC. Diabetes and cardiovascular disease: explaining the relationship. Rev Cardiovasc Med 2007; 8:145-153.

16. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358: 2545-2559.

17. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008, 358: 2560-2572.

18. Duckworth W, Abraira C, Moritz T et al. for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360: 129-139.

19. Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow-up of intensive glycemic control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-1589.

20. Cheng AY, Leiter LA. Glucose lowering and cardio-vascular disease: what do we know and what should we do? Eur J Cardiovasc Prev Rehabil, 2010, 17 (Suppl 1): 25-31.

21. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovacular outcomes in type 2 diabetes. Diabetologia, 2009, 52: 2288-2298. 22. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 2009, 373: 1765-1772.

22. Mannucci E, Monami M, Lamanna C et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis, 2009, 19: 604-612.

23. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probsteld JL, Schnall A, Seaquist ER. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Action to Control Cardiovascular Risk in Diabetes Investigators. Diabetes Care, 2010, 33: 983-90

24. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J, for the International Prandial Glucose Regulation (PGR) Study Group: Postprandial Glucose Regulation and Diabetic Complications. Arch Intern Med, 2004, 164: 2090-2095.

25. Nathan DM, Buse JB, Davidson MB, Hein RJ, Holman RR, Sherwin R et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006, 29: 1963-1972.

26. Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract, 2010, 64: 1705-11

27. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. Дедова И.И., Шестаковой М.В. Вып. 5: Сахарный диабет, 2011.

28. Сахарный диабет: диагностика, лечение, профилактика. Под ред. И.И. Дедова, М.В. Шестаковой. М.: ООО «Издательство “Медицинское информационное агентство”», 2011.

29. American Diabetes Association. Standards of medical care in diabetes -2012. Diabetes Care, 2012, 35, Suppl 1: 11-63.

30. http://www.idf.org/global-guideline-pregnancy-and-diabetes.

31. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. Дедова И.И., Шестаковой М.В. Вып. 6. 2013.

32. Raine CH, Schrock LE, Edelman SV, Mudaliar SRD, Zhong W, Proud L.J., Parkes JL. Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters. Journal of Diabetes Science and Technology, 2007, 1: 205-10.

33. Печатное издание ОООИ «Российская диабетическая ассоциация» №2/СД 2 2010 г. ПИ № ФС77-40852 от 05.07.2010.


Просмотров: 69


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)